世界卫生组织药物信息-第39卷第4号

Volume 39Number 4 2025 Proposed INN: List 134International Nonproprietary Names for Pharmaceutical Substances WHO Drug Information WHO Drug Information provides an overview of topics relating to medicines development, regulation, quality and safety. The journal alsopublishes and reports on guidance documents and includes lists of International Nonproprietary Names for Pharmaceutical Substances (INN),ATC/DDD classification and monographs for The International Pharmacopoeia. It presents and describes WHO policies and activities whilereflecting on technical and pharmaceutical topics of international and regional interest. WHO Drug Information is published four times a year and can be ordered from:WHO Press, World Health Organization, 1211 Geneva 27, Switzerland.e-mail:bookorders@who.intor on line athttp://www.who.int/bookorders WHO Drug Information can be viewed at:https://www.who.int/our-work/access-to-medicines-and-health-products/who-drug-information WHO Drug Information, Vol. 39, No. 4, 2025 ISBN 978-92-4-012052-5 (electronic version)ISBN 978-92-4-012053-2 (print version)ISSN 1010-9609 © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriatelycited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products orservices. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalentCreative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation:“This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of thistranslation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World IntellectualProperty Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. WHO Drug Information, Vol. 39, No. 4, 2025. Geneva: World Health Organization; 2025. Licence:CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available athttps://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders. To submit requests forcommercial use and queries on rights and licensing, seehttps://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is yourresponsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claimsresulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers.The designations employed and the presentation of the material in this publication do not imply the expression of anyopinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning thedelimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet befull agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO inpreference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products aredistinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material isbeing distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lieswith the reader. In no event shall WHO be liable for damages arising from its use. WHO Drug Information Contents PharmaceuticalNews 1061Thin-Layer Chromatography: A Valuable Tool in the Fight Against Substandard/Falsified Medicines Consultation Documents 1089Tenofovir Alafenamide Hemifumarate (tenofoviri alafenamidi hemifumaras)1103Diethylcarbamazine Tablets (diethylcarbamazini compressi)1108Cefiderocol Powder for Concentrate for Solution for Infusion (cefiderocoli pulvis pro concentrato pro solutione proinfusione)1115Cefiderocol Sulfate Tosilate (cefiderocoli sulfas tosilatum) Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) Classification 1125ATC/DDD Classification (Temporary)1128ATC/DDD Classification (Final) International Nonproprietary Names (INN) 11